← All trials
NCT06180057
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 12, 2022
- Primary completion
- Jul 18, 2022
- Completion date
- Aug 15, 2022
- First posted
- Dec 22, 2023
- Last posted
- Dec 28, 2023
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Humanis Saglık Anonim SirketiLead sponsor
- Humanis Saglık Anonim SirketiStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.